Navigation Links
Interferon might help asthma patients breathe easier, UT Southwestern study suggests
Date:7/13/2010

DALLAS July 15, 2010 An immune-system protein already used to treat diseases like multiple sclerosis, hepatitis C and a variety of cancers might also aid asthma patients, UT Southwestern Medical Center researchers have found.

The investigators determined that the protein interferon blocks the development of a population of immune cells known to cause asthma. These cells are members of a class of T lymphocytes, called T helper 2 cells, or Th2 cells. Under normal circumstances, Th2 cells help protect against infections by secreting chemicals that induce inflammation; however, in some individuals, these Th2 cells can also promote allergic responses to normally harmless substances, including animal dander, pollens and pollutants. Once Th2 cells become reactive to these substances, they promote all of the inflammatory processes common to allergic diseases like asthma and atopic dermatitis.

The findings, available online and in the July 15 issue of the Journal of Immunology, suggest that interferon might be a valuable and readily available therapy for individuals with asthma.

"This finding is incredibly important, because humans are being treated with interferon for a variety of diseases, yet no one has tried treating asthma patients with interferon," said Dr. J. David Farrar, assistant professor of immunology and molecular biology at UT Southwestern and senior author of the study. "The current therapies for asthma are inhalers and steroids, both of which offer only temporary relief."

Asthma results in approximately 200,000 pediatric hospitalizations each year, more than for any other childhood disease. About 20 million people have been diagnosed with asthma in the U.S.

In the current study, the researchers showed in isolated human cells that interferon blocks the development of nascent Th2 cells and inhibits cells that already have become Th2 cells by interfering with a regulatory protein called GATA3, a transcription factor Th2 cells express to regulate their function.

"Interferon is blocking the development of these cells and their stability, and it's doing this by targeting the very transcription factor that regulates their development and stability in the first place," Dr. Farrar said. "By targeting this transcription factor, we've turned off the key component that regulates the entire process."

The findings, he said, provide proof-of-principle that targeting this particular group of cells with interferon might be an effective therapy for those with asthma.

"The study has confirmed that it's the Th2 cells that you really want to target," he said. "If you can stop a Th2 cell from ever developing, and if you can take a Th2 cell that has already become one and stop it from secreting these asthma-causing chemicals, then that's really the 'Holy Grail' of treating asthma."

The next step, Dr. Farrar said, is to study whether interferon will prevent Th2 cells taken straight from asthma patients from secreting the chemicals known to induce asthma.

"If interferon works against these cells, I think that would be an excellent basis for beginning a clinical trial and treating asthma patients," Dr. Farrar said. "We've been treating humans with interferon for a long time, so we don't have to go through early-phase safety trials. We already have information about its toxicity."


'/>"/>

Contact: Kristen Holland Shear
kristen.hollandshear@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Vitamins D, E Might Help Maintain Brain Health
2. Taking Public Transit Might Help You Stay Slim
3. WIC might prevent mothers from feeding cows milk too early
4. MP3 Players Might Harm Hearing
5. Coffee Might Guard Against Head, Neck Cancers
6. Stomach Bacteria Might Trigger Rheumatoid Arthritis
7. World Cup Matches Might Boost Your Mental Health
8. Gene-Based Detection Method Might Spot HIV Earlier
9. Genetics, Insecticides Might Contribute to Parkinsons
10. Kids With Down Syndrome Might Get Help Learning
11. New Tests for Prostate Cancer Might Bring More Certainty
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... 2017 , ... Chicago plastic surgeon, Dr. Anil R. Shah, MD , ... benign bony lump located on the forehead usually attributed to a facial fracture. Their ... pain. Dr. Shah has discovered an approach that is minimally invasive. He is an ...
(Date:4/21/2017)... ... 2017 , ... Young Asset Protection, an insurance provider and ... greater Pittsburgh metropolitan region, is joining forces with the local chapter of the ... , Variety the Children’s Charity is a national organization dedicated to empowering, enabling, ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of The Beryl Institute ... 2017 Ruth Ravich Patient Advocacy Award in recognition of her extraordinary contributions to ... the award at The Beryl Institute’s annual Patient Experience Conference on March ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover Symmetry ... O2X , an active lifestyle company that provides Human Performance Training and education ... police offers, first responders, military officers and others in service through the development ...
(Date:4/21/2017)... ... April 21, 2017 , ... Airway ... new partnership with the highly regarded and well renowned Asian distributor, Discovery Sleep. ... & myTAP PAP Nasal Pillow Mask, and will stabilize and strengthen Airway’s presence ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, ... antibody-centric, clinical-stage biopharmaceutical company developing new treatments for ... the closing of its previously announced underwritten public ... at a public offering price of $2.00 per ... estimated offering expenses payable by Sorrento.  The net ...
Breaking Medicine Technology: